337 related articles for article (PubMed ID: 18688283)
61. Identification of Clotrimazole Derivatives as Specific Inhibitors of Arenavirus Fusion.
Torriani G; Trofimenko E; Mayor J; Fedeli C; Moreno H; Michel S; Heulot M; Chevalier N; Zimmer G; Shrestha N; Plattet P; Engler O; Rothenberger S; Widmann C; Kunz S
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626681
[TBL] [Abstract][Full Text] [Related]
62. Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis.
Köhler R; Wulff H; Eichler I; Kneifel M; Neumann D; Knorr A; Grgic I; Kämpfe D; Si H; Wibawa J; Real R; Borner K; Brakemeier S; Orzechowski HD; Reusch HP; Paul M; Chandy KG; Hoyer J
Circulation; 2003 Sep; 108(9):1119-25. PubMed ID: 12939222
[TBL] [Abstract][Full Text] [Related]
63. Blockade of KCa3.1 Attenuates Left Ventricular Remodeling after Experimental Myocardial Infarction.
Ju CH; Wang XP; Gao CY; Zhang SX; Ma XH; Liu C
Cell Physiol Biochem; 2015; 36(4):1305-15. PubMed ID: 26160442
[TBL] [Abstract][Full Text] [Related]
64. Blood-brain barrier KCa3.1 channels: evidence for a role in brain Na uptake and edema in ischemic stroke.
Chen YJ; Wallace BK; Yuen N; Jenkins DP; Wulff H; O'Donnell ME
Stroke; 2015 Jan; 46(1):237-44. PubMed ID: 25477223
[TBL] [Abstract][Full Text] [Related]
65. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
D'Alessandro G; Grimaldi A; Chece G; Porzia A; Esposito V; Santoro A; Salvati M; Mainiero F; Ragozzino D; Di Angelantonio S; Wulff H; Catalano M; Limatola C
Oncotarget; 2016 May; 7(21):30781-96. PubMed ID: 27096953
[TBL] [Abstract][Full Text] [Related]
66. Blockage of intermediate-conductance-Ca(2+) -activated K(+) channels inhibits progression of human endometrial cancer.
Wang ZH; Shen B; Yao HL; Jia YC; Ren J; Feng YJ; Wang YZ
Oncogene; 2007 Aug; 26(35):5107-14. PubMed ID: 17310992
[TBL] [Abstract][Full Text] [Related]
67. Targeting of microglial KCa3.1 channels by TRAM-34 exacerbates hippocampal neurodegeneration and does not affect ictogenesis and epileptogenesis in chronic temporal lobe epilepsy models.
Ongerth T; Russmann V; Fischborn S; Boes K; Siegl C; Potschka H
Eur J Pharmacol; 2014 Oct; 740():72-80. PubMed ID: 25016931
[TBL] [Abstract][Full Text] [Related]
68. Potassium channel changes of peripheral blood T-lymphocytes from Kazakh hypertensive patients in Northwest China and the inhibition effect towards potassium channels by telmisartan.
Zhang Q; Gou F; Zhang Y; He Y; He J; Peng L; Cheng L; Yuan Q; Zhang G; Huang S
Kardiol Pol; 2016; 74(5):476-488. PubMed ID: 26502942
[TBL] [Abstract][Full Text] [Related]
69. Neuronal expression of the intermediate conductance calcium-activated potassium channel KCa3.1 in the mammalian central nervous system.
Turner RW; Kruskic M; Teves M; Scheidl-Yee T; Hameed S; Zamponi GW
Pflugers Arch; 2015 Feb; 467(2):311-28. PubMed ID: 24797146
[TBL] [Abstract][Full Text] [Related]
70. Inhibition of KCa3.1 suppresses TGF-β1 induced MCP-1 expression in human proximal tubular cells through Smad3, p38 and ERK1/2 signaling pathways.
Huang C; Day ML; Poronnik P; Pollock CA; Chen XM
Int J Biochem Cell Biol; 2014 Feb; 47():1-10. PubMed ID: 24291552
[TBL] [Abstract][Full Text] [Related]
71. Genetic Evidence Supports a Major Role for Akt1 in VSMCs During Atherogenesis.
Rotllan N; Wanschel AC; Fernández-Hernando A; Salerno AG; Offermanns S; Sessa WC; Fernández-Hernando C
Circ Res; 2015 May; 116(11):1744-52. PubMed ID: 25868464
[TBL] [Abstract][Full Text] [Related]
72. Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade.
Grössinger EM; Weiss L; Zierler S; Rebhandl S; Krenn PW; Hinterseer E; Schmölzer J; Asslaber D; Hainzl S; Neureiter D; Egle A; Piñón-Hofbauer J; Hartmann TN; Greil R; Kerschbaum HH
Leukemia; 2014 Apr; 28(4):954-8. PubMed ID: 24441290
[No Abstract] [Full Text] [Related]
73. The calcium-activated potassium channel KCa3.1 plays a central role in the chemotactic response of mammalian neutrophils.
Henríquez C; Riquelme TT; Vera D; Julio-Kalajzić F; Ehrenfeld P; Melvin JE; Figueroa CD; Sarmiento J; Flores CA
Acta Physiol (Oxf); 2016 Jan; 216(1):132-45. PubMed ID: 26138196
[TBL] [Abstract][Full Text] [Related]
74. New Insights on KCa3.1 Channel Modulation.
Manfroni G; Ragonese F; Monarca L; Astolfi A; Mancinelli L; Iannitti RG; Bastioli F; Barreca ML; Cecchetti V; Fioretti B
Curr Pharm Des; 2020; 26(18):2096-2101. PubMed ID: 32175839
[TBL] [Abstract][Full Text] [Related]
75. Efficacy of combined tumor irradiation and K
Stransky N; Ganser K; Quintanilla-Martinez L; Gonzalez-Menendez I; Naumann U; Eckert F; Koch P; Huber SM; Ruth P
Sci Rep; 2023 Nov; 13(1):20604. PubMed ID: 37996600
[TBL] [Abstract][Full Text] [Related]
76. Calcium-gated K
Tarasov MV; Bystrova MF; Kotova PD; Rogachevskaja OA; Sysoeva VY; Kolesnikov SS
Pflugers Arch; 2017 Feb; 469(2):349-362. PubMed ID: 28028617
[TBL] [Abstract][Full Text] [Related]
77. Functional Roles of the Ca2+-activated K+ Channel, KCa3.1, in Brain Tumors.
D'Alessandro G; Limatola C; Catalano M
Curr Neuropharmacol; 2018; 16(5):636-643. PubMed ID: 28707595
[TBL] [Abstract][Full Text] [Related]
78. Inhibition of Interleukin 10 Transcription through the SMAD2/3 Signaling Pathway by Ca
Matsui M; Kajikuri J; Kito H; Endo K; Hasegawa Y; Murate S; Ohya S
Mol Pharmacol; 2019 Mar; 95(3):294-302. PubMed ID: 30622214
[TBL] [Abstract][Full Text] [Related]
79. KCa3.1 Transgene Induction in Murine Intestinal Epithelium Causes Duodenal Chyme Accumulation and Impairs Duodenal Contractility.
Valero MS; Ramón-Gimenez M; Lozano-Gerona J; Delgado-Wicke P; Calmarza P; Oliván-Viguera A; López V; Garcia-Otín ÁL; Valero S; Pueyo E; Hamilton KL; Miura H; Köhler R
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30857243
[No Abstract] [Full Text] [Related]
80. The Ca2+-activated K+ channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration.
Kaushal V; Koeberle PD; Wang Y; Schlichter LC
J Neurosci; 2007 Jan; 27(1):234-44. PubMed ID: 17202491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
